Author

J. Xiu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Beck· 1 shared B. Bui· 1 shared B. Faezov· 1 shared C. K. Petritsch· 1 shared D. Hambardzumyan· 1 shared D. Panovska· 1 shared E. Nasajpour· 1 shared E. V. Demidova· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Beck

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune CheckpointSensitivity in BRAFV600E-mutant Glioma

Y. L. Xing, D. Panovska, J.-W. Park, S. Grossauer, K. Koeck, B. Bui, E. Nasajpour, J. J. Nirschl, Z.-P. Feng, P. Cheung, P. Habib, R. Wei, J. Wang, W. Thomason, J. Xiu, , C. K. Petritsch

This study shows that BRAF/MEK inhibition induces cell state transitions in BRAFV600E-mutant gliomas, leading to PD-L1 upregulation and immune evasion, which can be overcome by combining with immune checkpoint inhibition.

bioRxiv · Feb 3, 2023Cancer Biology

Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumors.

S. S. Shah, E. V. Demidova, S. Ringenbach, B. Faezov, M. Andrake, P. Mur, J. Viana-Errasti, J. Xiu, J. Swensen, L. Valle, R. Dunbrack, M. J. Hall, S. Arora

The paper identifies co-occurring POLE mutations in both exonuclease and non-exonuclease domains as a novel driver of ultra-high tumor mutation burden in certain cancers.

bioRxiv · Dec 15, 2022 · PreprintCancer Biology